 |
 |
--------- Forwarded message ---------- From: WE MOVE <[log in to unmask]> To: <[log in to unmask]> Date: Mon, 6 Aug 2001 23:06:26 -0500 Subject: High-Dose Ropinirole (PD Congress 2001) Message-ID: <[log in to unmask]> E-MOVE reports from the 14th International Congress on Parkinson's Disease, Helsinki July 28-Aug 1. Poster and Platform session numbers refer to those in the abstract book, published in Parkinsonism and Related Disorders 2001;7(Supplement). High-dose ropinirole allows reduction in levodopa and lessening of dyskinesias in advanced PD patients, according to these two studies. 1. Efficacy and tolerability of high dose ropinirole in patients with Parkinson's disease (PD) and levodopa-induced late motor complications UF Polzer, H Hundt P-TU-222 Twenty-one patients increased their mean ropinirole dose from 8.2 mg/day to 29.7 mg/day, and their daily levodopa dose from 770 mg/day to 555 mg/day (p<0.001), over a period of 8 weeks or less. After 12 weeks, duration of daily dyskinesia was reduced from 30.4% of the day to 4.6%, while "off" periods were reduced from 42.6% to 14.6%. Four patients developed psychotic symptoms. One patient withdrew due to psychosis, and six others for reasons believed to be unconnected to treatment. Supported by SmithKline Beecham 2. High-dose ropinirole in advanced Parkinson's disease C Pacchetti, F Mancini, R Zangaglia, S Cristina, F Blandini, E Martignoni P-TU-219 Thirty-six patients increased their mean dose of ropinirole from 16 mg/day to 35 mg/day, and reduced levodopa from 752 mg/day to 588 mg/day (p=0.001). Dyskinesias during "on" were reduced 40%, and dystonia during "off" was reduced by 40%. No treatment-emergent side effects were reported. --- Funding for E-MOVE meeting reports is provided in part by unrestricted educational grants from Allergan Inc., Elan Pharmaceuticals, and Pharmacia Corporation. Copyright 2000 WE MOVE Editor: Richard Robinson ([log in to unmask]) This service is provided free of charge to the Internet community, courtesy of WEMOVE.org. This document may be freely redistributed by email only in its unedited form. We encourage you to share it with your colleagues. E-MOVE archives, plus information on subscribing, are available at http://www.wemove.org/emove. To unsubscribe, send an e-mail to [log in to unmask], with "unsubscribe e-move" in the message body. E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for Movement Disorders) 204 West 84th Street New York, NY 10024 TEL 800-437-MOV2 TEL 212-875-8312 FAX 212-875-8389 http://www.wemove.org ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn